[1] BINH VU*. Discovery of RG7112: A Small-Molecule MDM2 Inhibitor in Clinical Development[J]. ACS Medicinal Chemistry Letters, 2013, 4 5: 466-469. DOI:
10.1021/ml4000657[2] CHRISTIAN TOVAR. MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models.[J]. Cancer research, 2013, 73 8: 2587-2597. DOI:
10.1158/0008-5472.can-12-2807[3] CAMELIA IANCU-RUBIN . Activation of p53 by the MDM2 inhibitor RG7112 impairs thrombopoiesis[J]. Experimental hematology, 2014, 42 2: Pages 137-145.e5. DOI:
10.1016/j.exphem.2013.11.012